Marc Martinez-Llordella

Marc Martinez-Llordella

Company: Quell Therapeutics

Job title: Founder & Vice President Biology

Seminars:

Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic 3:45 pm

• Rational and preliminary data to support the use of antigen-specific Tregs as a therapeutic approach • Engineering technologies to improve Treg efficacy in the clinical applicationRead more

day: Day 2 - Track B - Evening

Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic 11:30 am

Rational and preliminary data to support the use of antigen-specific Tregs as a therapeutic approach Engineering technologies to improve Treg efficacy in the clinical application      Read more

day: Focus Day - Track A - Afternoon

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.